Related Experiment Video

Updated: Jul 13, 2026

Generation of Human Nasal Epithelial Cell Spheroids for Individualized Cystic Fibrosis Transmembrane Conductance Regulator Study
08:00

Generation of Human Nasal Epithelial Cell Spheroids for Individualized Cystic Fibrosis Transmembrane Conductance Regulator Study

Published on: April 11, 2018

An overview of endpoints for cystic fibrosis clinical trials: one size does not fit all

Margaret Rosenfeld1

  • 1Division of Pulmonary Medicine, Department of Pediatrics, University of Washington School of Medicine, Seattle, Washington, USA. margaret.rosenfeld@seattlechildrens.org

Proceedings of the American Thoracic Society
|July 27, 2007
PubMed

Insights

Clinical trials for cystic fibrosis (CF) require diverse endpoints to evaluate new therapies. This review discusses current and emerging outcome measures, including imaging, to assess treatment efficacy.

Area of Science:

  • Pulmonology and Respiratory Medicine
  • Clinical Trial Design
  • Biomedical Imaging

Background:

  • Cystic Fibrosis (CF) research is advancing with novel therapeutics like gene therapy, anti-inflammatories, and anti-infectives.
  • Evaluating these diverse CF treatments necessitates a comprehensive set of clinical trial endpoints.
  • The current endpoint 'toolbox' for CF trials includes lung function, exacerbation rates, quality of life, and various imaging techniques.

Purpose of the Study:

  • To review the qualities of an ideal outcome measure for CF clinical trials.
  • To identify the advantages and limitations of existing CF clinical trial endpoints.
  • To discuss the role of chest computed tomography (CT) and emerging imaging modalities as surrogate endpoints in CF research.

Main Methods:

  • Review of existing literature on clinical trial endpoints in cystic fibrosis.
  • Distinction between clinical and surrogate endpoints, with imaging classified as a surrogate endpoint.
  • Analysis of the strengths and weaknesses of current CF outcome measures.

Main Results:

  • Current CF trial endpoints encompass a range of measures including pulmonary exacerbation rates, quality of life, growth, lung function, and imaging.
  • Chest CT and newer imaging modalities are valuable surrogate endpoints but require careful consideration.
  • The selection of appropriate endpoints must be tailored to specific therapeutic indications and trial objectives.

Conclusions:

  • A robust and varied set of endpoints is crucial for accurately assessing novel cystic fibrosis therapeutics.
  • Chest CT and advanced imaging offer promising surrogate endpoints, complementing traditional clinical measures.
  • Strategic selection of endpoints is paramount for successful clinical trial design in cystic fibrosis research.

More Related Videos

Forskolin-induced Swelling in Intestinal Organoids: An In Vitro Assay for Assessing Drug Response in Cystic Fibrosis Patients07:04

Forskolin-induced Swelling in Intestinal Organoids: An In Vitro Assay for Assessing Drug Response in Cystic Fibrosis Patients

Published on: February 11, 2017

Standardized Measurement of Nasal Membrane Transepithelial Potential Difference (NPD)09:47

Standardized Measurement of Nasal Membrane Transepithelial Potential Difference (NPD)

Published on: September 13, 2018

Related Concept Videos

Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic sinusitis...
Cystic Fibrosis: Pathogenesis01:23

Cystic Fibrosis: Pathogenesis

Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation, but...
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence01:27

Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence

Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
Dosage Regimen: Individualization01:24

Dosage Regimen: Individualization

Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...